A detailed history of Black Rock Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 5,494,591 shares of APLS stock, worth $211 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,494,591
Previous 5,381,253 2.11%
Holding current value
$211 Million
Previous $322 Million 0.26%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$55.39 - $72.47 $6.28 Million - $8.21 Million
113,338 Added 2.11%
5,494,591 $323 Million
Q4 2023

Feb 13, 2024

BUY
$37.14 - $64.82 $4.03 Million - $7.03 Million
108,507 Added 2.06%
5,381,253 $322 Million
Q3 2023

Nov 13, 2023

SELL
$23.65 - $89.22 $11.2 Million - $42.4 Million
-474,881 Reduced 8.26%
5,272,746 $201 Million
Q2 2023

Aug 11, 2023

SELL
$76.68 - $93.31 $146 Million - $178 Million
-1,907,824 Reduced 24.92%
5,747,627 $524 Million
Q1 2023

May 12, 2023

SELL
$46.59 - $66.96 $2.27 Million - $3.26 Million
-48,743 Reduced 0.63%
7,655,451 $505 Million
Q4 2022

Feb 13, 2023

BUY
$43.24 - $61.04 $26.7 Million - $37.7 Million
617,864 Added 8.72%
7,704,194 $398 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $12.9 Million - $20 Million
287,786 Added 4.23%
7,086,330 $484 Million
Q2 2022

Aug 12, 2022

BUY
$35.07 - $59.21 $30.7 Million - $51.8 Million
874,624 Added 14.76%
6,798,544 $307 Million
Q1 2022

May 12, 2022

BUY
$35.46 - $54.12 $2.06 Million - $3.15 Million
58,208 Added 0.99%
5,923,920 $301 Million
Q4 2021

Feb 10, 2022

BUY
$30.74 - $49.16 $12.3 Million - $19.6 Million
399,521 Added 7.31%
5,865,712 $277 Million
Q3 2021

Nov 09, 2021

SELL
$31.4 - $69.84 $6.42 Million - $14.3 Million
-204,541 Reduced 3.61%
5,466,191 $180 Million
Q2 2021

Aug 11, 2021

BUY
$40.9 - $64.9 $232 Million - $368 Million
5,670,732 New
5,670,732 $358 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.21B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.